Search results for "Angiotensin"

showing 10 items of 396 documents

Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synth…

2011

Continuous administration of nitroglycerin (GTN) causes tolerance and endothelial dysfunction by inducing reactive oxygen species (ROS) production from various enzymatic sources, such as mitochondria, NADPH oxidase, and an uncoupled endothelial nitric oxide synthase (eNOS). In the present study, we tested the effects of type 1 angiotensin (AT(1))-receptor blockade with telmisartan on GTN-induced endothelial dysfunction in particular on eNOS phosphorylation and S-glutathionylation sites and the eNOS cofactor synthesizing enzyme GTP-cyclohydrolase I.Wistar rats were treated with telmisartan (2.7 or 8 mg/kg per day PO for 10 days) and with GTN (50 mg/kg per day SC for 3 days). Aortic eNOS phos…

MaleNitric Oxide Synthase Type IIIPhysiologyVasodilator AgentsPharmacologyBenzoatesCell LineNitroglycerinmedicineAnimalsHumansTelmisartanEnzyme InhibitorsPhosphorylationRats WistarS-GlutathionylationEndothelial dysfunctionGTP CyclohydrolaseBeneficial effectsNitroglycerinPharmacologyAngiotensin II receptor type 1Dose-Response Relationship DrugEndothelial nitric oxide synthaseChemistryEndothelial CellsDrug ToleranceAldehyde Dehydrogenasemedicine.diseaseGlutathioneMitochondriaRatsVasodilationOxidative StressTetrahydrofolate DehydrogenaseMolecular MedicinePhosphorylationBenzimidazolesEndothelium VascularTelmisartanReactive Oxygen SpeciesAngiotensin II Type 1 Receptor BlockersProtein Processing Post-Translationalmedicine.drugVascular Pharmacology
researchProduct

Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction…

2006

Background— Individual markers of inflammation may add incremental predictive value in the context of conventionally available risk factors. We evaluated the ability of 9 inflammatory biomarkers, microalbuminuria, and N-terminal pro-brain natriuretic peptide (Nt-proBNP) to improve cardiovascular risk prediction beyond that obtained from traditional risk factors in a secondary-prevention population. Methods and Results— We measured biomarkers representing the acute-phase reaction (C-reactive protein, fibrinogen, and interleukin-6), proinflammatory pathways (soluble tumor necrosis factor receptor-1 and -2, soluble interleukin-1 receptor antagonist, and interleukin-18), endothelial activation…

MaleOncologymedicine.medical_specialtyHeart Diseasesmedicine.drug_classPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsContext (language use)Coronary Artery DiseaseProinflammatory cytokineEndothelial activationRamiprilPredictive Value of TestsRisk FactorsPhysiology (medical)Internal medicineNatriuretic Peptide BrainNatriuretic peptideHumansVitamin EMedicineRisk factoreducationAgededucation.field_of_studyInterleukin-6business.industryFibrinogenMiddle Agedmedicine.diseaseBrain natriuretic peptideC-Reactive ProteinEndocrinologyFemaleMicroalbuminuriaCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Arterial and Venous Endothelia Display Differential Functional Fractalkine (CX 3 CL1) Expression by Angiotensin-II

2012

Objective— Angiotensin-II (Ang-II) promotes the interaction of mononuclear cells with arterioles and neutrophils with postcapillary venules. To investigate the mechanisms underlying this dissimilar response, the involvement of fractalkine (CX 3 CL1) was explored. Methods and Results— Enhanced CX 3 CL1 expression was detected in both cremasteric arterioles and postcapillary venules 24 hours after Ang-II intrascrotal injection. Arteriolar leukocyte adhesion was the unique parameter significantly reduced (83%) in animals lacking CX 3 CL1 receptor (CX 3 CR1). Human umbilical arterial and venous endothelial cell stimulation with 1 μmol/L Ang-II increased CX 3 CL1 expression, yet neutralization …

MalePathologyTime Factorsp38 Mitogen-Activated Protein KinasesMiceVenulesLeukocytesEndothelial dysfunctionExtracellular Signal-Regulated MAP KinasesReceptorCells CulturedMice KnockoutMembrane GlycoproteinsAngiotensin IINF-kappa BArteriesEndothelial stem cellArteriolesNADPH Oxidase 5NADPH Oxidase 4NADPH Oxidase 2FemaleRNA InterferenceReceptors ChemokineTumor necrosis factor alphaCardiology and Cardiovascular MedicineSignal Transductionmedicine.medical_specialtyCX3C Chemokine Receptor 1BiologyTransfectionPeripheral blood mononuclear cellLosartanVeinsInterferon-gammaApolipoproteins EDownregulation and upregulationInternal medicineCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansLeukocyte RollingCX3CL1Chemokine CX3CL1Tumor Necrosis Factor-alphaEndothelial CellsMembrane ProteinsNADPH OxidasesAtherosclerosismedicine.diseaseAngiotensin IIMice Inbred C57BLDisease Models AnimalEndocrinologyAngiotensin II Type 1 Receptor BlockersArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk

2015

Abstract— Elevated systolic blood pressure (SBP) correlates to cognitive decline and incident dementia. The effects of heart rate (HR), visit to visit HR variation, and visit to visit SBP variation are less well established. Patients without preexisting cognitive dysfunction (N=24 593) were evaluated according to mean SBP, SBP visit to visit variation (coefficient of variation [standard deviation/mean×100%], CV), mean HR, and visit to visit HR variation (HR-CV) in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Cognitive function was assessed with min…

MalePredictive Value of TestAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzimidazoleBenzoatesRamiprilRetrospective StudieHeart RateRisk FactorsCardiovascular DiseaseTelmisartanCognitive declineMultivariate AnalysiRandomized Controlled Trials as TopicAged 80 and overmedicine.diagnostic_testIncidenceMiddle AgedstrokeAntihypertensive Agentmyocardial infarctionCardiovascular DiseasesHypertensionCardiologyDrug Therapy CombinationFemaleHumanmedicine.drugRamiprilmedicine.medical_specialtyBenzoateFollow-Up StudieCognition DisorderPredictive Value of TestsInternal medicineHeart rateInternal MedicinemedicineHumansDementiaAntihypertensive AgentsAgedRetrospective StudiesMini–Mental State Examinationbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratiomedicine.diseaseConfidence intervalBlood pressureMultivariate AnalysisPhysical therapyBenzimidazolesCognition DisordersbusinessFollow-Up StudiesHypertension
researchProduct

Transforming growth factor β1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive s…

2005

Objective To verify the benefit of renin–angiotensin system blockade in hypertension, the effects of 24 weeks’ losartan and ramipril treatment, both alone and in combination, on urinary albumin excretion (UAE) and circulating transforming growth factor b1 (TGFb1) have been evaluated in hypertensive subjects with minor renal abnormalities. Design and methods Fifty-one patients with stage 1 and 2 essential hypertension and with UAE >—20 mg/24 h but with maintained renal function have been included. After a 4-week run-in with placebo administration, a randomized double-blind, three-arm double-dummy trial was used. All the hypertensives (HT) were allocated randomly to three treatment arms (1…

MaleRamiprilmedicine.medical_specialtyAngiotensin receptorHypertension RenalPhysiologyAngiotensin-Converting Enzyme InhibitorsPharmacologyKidneySeverity of Illness IndexLosartanAce-inhibitors Angiotensin II receptor blockers hypertensive renal disease transforming growth factor β1.Transforming Growth Factor beta1transforming growth factor b1RamiprilTransforming Growth Factor betaInternal medicineInternal MedicinemedicineHumansRenal Insufficiencybusiness.industryMiddle AgedAngiotensin IIBlockadeangiotensin II receptor blockerEndocrinologyLosartanhypertensive renal diseaseRenal physiologyACE inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessangiotensin-converting enzyme-inhibitorAngiotensin II Type 1 Receptor BlockersBiomarkersTransforming growth factormedicine.drug
researchProduct

Angiotensin-Converting Enzyme Inhibitor Use and Incident Frailty: A Longitudinal Cohort Study

2019

Introduction: Angiotensin-converting enzyme inhibitors (ACEI) may have several pleiotropic effects, but the literature regarding a possible relationship between ACEI use and frailty is limited. We investigated whether ACEI use is associated with lower risk of frailty in a cohort of North American individuals. Methods: Data from the Osteoarthritis Initiative, a cohort study with 8 years of follow-up including community-dwelling adults with knee osteoarthritis or at high risk for this condition, were analyzed. ACEI use was defined through self-reported information and confirmed by a trained interviewer. Frailty was defined using the Study of Osteoporotic Fracture (SOF) index as the presence o…

MaleRiskmedicine.medical_specialtyA Longitudinal Cohort Study.- Drugs & aging cilt.36 ss.387-393 2019 [VERONESE N. STUBBS B. SMITH L. MAGGI S. JACKSON S. Soysal P. DEMURTAS J. CELOTTO S. KOYANAGI A. -Angiotensin-Converting Enzyme Inhibitor Use and Incident Frailty]Angiotensin-Converting Enzyme InhibitorsLower riskCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineWeight LossmedicineHumansPharmacology (medical)Longitudinal Studiescardiovascular diseases030212 general & internal medicinePoisson regressionPropensity ScoreAgedFrailtybusiness.industryConfoundingMiddle AgedOsteoarthritis KneeConfidence intervalcarboxypeptidasecaptoprilinhibitorRelative riskNorth AmericaPropensity score matchingCohortsymbolsFemaleIndependent LivingSelf ReportGeriatrics and Gerontologybusinessdipeptidyl030217 neurology & neurosurgeryCohort studyDrugs & Aging
researchProduct

The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary hea…

2004

To analyse the relation between overweight, obesity and fat distribution with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene and its association with coronary heart disease (CHD). Cross-sectional, case–control study. A total of 185 cases (141 males) who had suffered at least one episode of CHD and 182 controls (127 males). Body mass index, waist circumference, blood pressure, plasma total cholesterol, triglycerides, HDL cholestrol and fasting glucose were measured with standard methods, genotyping the I/D polymorphism of ACE gene. Obesity and abdominal fat deposit are associated with CHD in women, but not independently. We have found an association between obesity and abdo…

MaleRiskmedicine.medical_specialtyWaistGenotypeEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Coronary DiseaseOverweightPeptidyl-Dipeptidase APolymorphism (computer science)Internal medicineAbdomenMedicineHumansObesityAgedNutrition and DieteticsPolymorphism Geneticbiologybusiness.industryCase-control studyAngiotensin-converting enzymeMiddle Agedmedicine.diseaseObesityBlood pressureEndocrinologyCross-Sectional StudiesLogistic ModelsAdipose TissueCase-Control Studiesbiology.proteinBody ConstitutionFemalemedicine.symptombusinessBody mass indexInternational journal of obesity (2005)
researchProduct

Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygena…

2002

Angiotensin II (Ang II) may be a key molecule in the development of atherosclerosis. Because the incidence of coronary atherosclerosis in premenopausal women is lower than that observed in men or postmenopausal women, we have investigated the effect of estrogens on Ang II–induced leukocyte recruitment in vivo using intravital microscopy in the rat mesenteric microcirculation. Superfusion for 60 minutes with Ang II induced a significant increase in leukocyte rolling flux, adhesion, and emigration. Administration of 17-β-estradiol (17-β-E) after 30 minutes of Ang II superfusion produced a reduction of these leukocyte responses by 55.1%, 72.7%, and 70.9%, respectively, an additional 30 minutes…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyEndotheliumPhysiologyLeukocyte RollingProstacyclinCell CommunicationBiologyIn Vitro TechniquesLosartanReceptor Angiotensin Type 1Lymphatic SystemRats Sprague-DawleyAngiotensin Receptor AntagonistsCell MovementInternal medicinemedicineCell AdhesionLeukocytesAnimalsHumansSplanchnic CirculationEnzyme InhibitorsCells CulturedVenuleEstradiolAngiotensin IIEstrogen AntagonistsAntibodies MonoclonalEstrogensAngiotensin IIEpoprostenolRatsEndothelial stem cellNitric oxide synthasemedicine.anatomical_structureEndocrinologyProstaglandin-Endoperoxide Synthasesbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsIntravital microscopymedicine.drugCirculation research
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Serum uric acid is not independently associated with plasma renin activity and plasma aldosterone in hypertensive adults

2017

Background and Aims In experimental investigations conducted in rats, raising serum uric acid (SUA) levels resulted in the stimulation of intrarenal renin expression. Studies in humans exploring the association of SUA with plasma renin activity (PRA) yielded conflicting results. Moreover, little is known about the relationship of SUA with plasma aldosterone concentration (PAC). The study aimed to assess the relationship between SUA levels, PRA, and PAC and the influence of age, gender, body mass index (BMI), and hyperuricemia on these relationships in subjects with essential hypertension (EH). Methods and Results We enrolled 372 hypertensive patients (mean age 45 ± 12 years, men 67%) with u…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologyEssential hypertensionKidneyPlasma renin activityRenin-Angiotensin Systemchemistry.chemical_compound0302 clinical medicineRisk FactorsReninNutrition and Dietetic030212 general & internal medicineHyperuricemiaAldosteroneAdiposityNutrition and DieteticsAldosteroneAge FactorsMiddle AgedHypertensionBlood pressureFemaleCardiology and Cardiovascular MedicineAdultArterial hypertensionmedicine.medical_specialtyRenal functionHyperuricemiaEssential hypertension03 medical and health sciencesSex FactorsPlasma renin activityPlasma aldosteroneInternal medicinemedicineHumansSettore MED/14 - NefrologiaCreatinineChi-Square Distributionbusiness.industrymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyCross-Sectional StudieschemistryMultivariate AnalysisLinear ModelsUric acidbusinessBody mass indexUric acidBiomarkers
researchProduct